1-1 of 1
Michael Datto, M.D.
Close
Sort by
Journal Articles

Cenersen, An Antisense Inhibitor of p53, in Combination with Fludarabine, Cyclophosphamide, and Rituximab Shows Clinical Activity in High Risk CLL.

Mark C Lanasa, MD, PhD, Patricia H Davis, R.N, Michael Datto, M.D., Harry Cook, RPh, MBA, David A. Rizzieri, MD
Journal: Blood
Blood (2009) 114 (22): 3430.
https://doi.org/10.1182/blood.V114.22.3430.3430
Published: 2009